Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has downgraded Seelos Therapeutics (NASDAQ:SEEL) from Overweight to Neutral.

September 21, 2023 | 8:36 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Seelos Therapeutics has been downgraded from Overweight to Neutral by Cantor Fitzgerald.
Analyst ratings can significantly influence the stock price. A downgrade from Overweight to Neutral suggests that the analyst sees less upside potential in the stock, which could lead to selling pressure and a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100